Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.48 |
| ▸ | KRAS | P01116 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17489495 | 0.80 | ALDH1A1 (0.42) | HRASKRASALDH1A1MEN1KMT2A | |
| SCHEMBL17486851 | 0.79 | HRAS (0.69) | HRASKRASALDH1A1MEN1KMT2A | |
| SCHEMBL16056750 | 0.79 | TEAD4 (0.53) | HRASKRASALDH1A1MEN1KMT2A | |
| SCHEMBL17486853 | 0.78 | BCHE (0.51) | ALDH1A1MEN1KMT2ALMNAGAA | |
| SCHEMBL24370532 | 0.74 | ALDH1A1 (0.63) | ALDH1A1LMNASMN1; SMN2GAATPSAB1 | |
| SCHEMBL11605746 | 0.72 | CYP1A2 (0.75) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9568696 | 0.72 | ALDH1A1 (0.59) | ALDH1A1LMNASMN1; SMN2GAATPSAB1 | |
| SCHEMBL9766713 | 0.70 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9067743 | 0.70 | CA12 (0.62) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6290158 | 0.70 | ALDH1A1 (0.66) | ALDH1A1LMNASMN1; SMN2GAATPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745319-B2 | Irreversible covalent inhibitors of the GTPase K-Ras G12C | ARAXES PHARMA LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745319-B2 | Irreversible covalent inhibitors of the GTPase K-Ras G12C | ARAXES PHARMA LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160031898-A1 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C | ARAXES PHARMA LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031898-A1 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C | ARAXES PHARMA LLC | 2016-02-04 | — | — | US | disclosed |
| WO-2014143659-A1 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C | ARAXES PHARMA LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143659-A1 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C | ARAXES PHARMA LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031898-A1 | IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C | KRAS, HRAS, NRAS | HRAS 2/4885KRAS 1/4885ALDH1A1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.